November 2011
American Journal of Health-System Pharmacy;11/15/2011, Vol. 68 Issue 22, p2103
Academic Journal
The article offers updates on recent research as of November 15, 2011. Eating a high-fat breakfast before a 10-mg dose of dalfampridine improves the plasma drug strength in healthy people. There is no proof of link between the use of angiotensin II-receptor blockers and development of lung, breast or prostate cancer. A hospital increased its overall rate of pharmacologic prophylaxis for patients at high risk for venous thromboembolism (VTE) using the best-practice guidelines.


Related Articles

  • BLOOD PRESSURE DRUGS, LIP CANCER RISK MAY BE LINKED, RESEARCH SHOWS.  // Journal of the American Dental Association (JADA);Nov2012, Vol. 143 Issue 11, p1186 

    The article mentions the study made by the Researchers at the Kaiser Permanente Northern California Division of Research in Oakland that showed that the risk of developing squamous cell lip cancer was higher among those non-Hispanic whites administered with long-term treatment with...

  • OF SPECIAL INTEREST.  // American Journal of Health-System Pharmacy;4/15/2012, Vol. 69 Issue 8, p621 

    The article offers brief information on the topics discussed in articles within the issue. A recombinant protein, ecallantide, used for the treatment of acute attacks of hereditary angioedema. A study showing that cirrhotic patients with an elevated International Normalized Ratio should be...

  • Angiotensin receptor blockers and cancer: safety review.  // WHO Drug Information;2010, Vol. 24 Issue 4, p301 

    The article discusses a 2010 decision which the U.S. Food and Drug Administration made to conduct a review of the class of medications known as angiotensin receptor blockers after a study was published which suggested the medications may be associated with a small increased risk of cancer.

  • Cancer history increases chances of VTE after knee arthroscopy, study finds. Press, Robert // Orthopedics Today;Dec2011, Vol. 31 Issue 12, p50 

    The article focuses on a study which found that history of cancer and venous thromboembolism are significant risk factors for venous thromboembolism following knee arthroscopy.

  • Lisinopril.  // Reactions Weekly;10/23/2010, Issue 1324, p25 

    The article describes a case of angioedema in a 55-year-old hypertensive woman who was receiving lisinopril.

  • Lisinopril.  // Reactions Weekly;5/5/2012, Issue 1400, p28 

    The article describes the case of a patient who developed angioedema while receiving treatment with lisinopril for hypertension.

  • Rivaroxaban for VTE prevention.  // Internal Medicine Alert;3/15/2013 Pharmacology Watch, p2 

    The article suggests the use of Rivaroxaban, the oral Xa inhibitor in preventing venous thromboembolism (VTE) in patients with acute medical illnesses.

  • Secondary prevention of venous thromboembolism. Schulman, Sam; Douketis, James // BMJ: British Medical Journal;9/14/2013, Vol. 347 Issue 7924, p10 

    The authors reflects on the findings of research which dealt with the effectiveness of emerging anticoagulation treatments for preventing unprovoked venous thromboembolism. They note the only trial that pitted two anticoagulants, namely dabigatran and warfarin. They cite studies which...

  • Angioedema often recurs after stopping ACE inhibitors.  // Reactions Weekly;11/26/2011, Issue 1379, p5 

    The article reports that approximately 50% of patients with angiotensin-converting enzyme inhibitor-related angioedema experienced further relapses of angioedema following transition to another antihypertensive, according to the findings of a 2011 research study conducted in Italy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics